Pharmaceutical News

RSS

Shingles vaccine can help protect elderly patients with end-stage renal disease

Elderly patients with end-stage renal disease (ESRD) who received the shingles vaccine were half as likely to develop shingles compared to those who were not vaccinated. The new study from Kaiser Permanente, published in Clinical Infectious Diseases, also found the best protection against shingles was achieved when patients received the vaccination shortly after beginning dialysis.

16 Dec 2015

TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan

TaiGen Biotechnology Company, Limited today announced that together with its distribution partner, Holding Distribution, it has launched Taigexyn (nemonoxacin) capsules in Taiwan, the first market where Taigexyn is available.

16 Dec 2015

Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.

16 Dec 2015

SLU researcher discovered world's first dengue vaccine

A vaccine to prevent dengue fever discovered by a Saint Louis University researcher in 1997 and now licensed worldwide by Sanofi Pasteur has been approved for use in Mexico. Dengvaxia is the world's first vaccine approved to prevent dengue fever, which is a virus spread by mosquitoes primarily in tropical and sub-tropical areas.

15 Dec 2015

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

15 Dec 2015

Researchers discover first broad spectrum drug that can potently kill aging cells in culture

Researchers from the University of Arkansas for Medical Sciences and other institutions are reporting the discovery of the first broad spectrum drug that can potently kill senescent (or aging) cells in culture and effectively clear the cells in animals by specifically targeting a pathway that is critical for the survival of senescent cells.

15 Dec 2015

Flu vaccine strategy needs to be reworked, York U study finds

In the face of a flu epidemic, a one-size fits all vaccine strategy won't be effective, a York University study has found. Instead, strategies need to change significantly depending on the characteristics of each region in Canada and how easily the particular flu strain spreads.

15 Dec 2015

Global Health Impact Index can measure actual impact of drugs worldwide

Billions of dollars have been spent on developing drugs and supplying them around the world, but which companies' drugs are actually making an impact? The Global Health Impact Index, headed by Binghamton University Associate Professor Nicole Hassoun and highlighted in a new article published Friday in PLOS ONE, addresses this issue by ranking pharmaceutical companies based on their drugs' impact on global health.

15 Dec 2015

VistaPharm announces launch of Potassium Chloride Solution

VistaPharm today announced that it has launched Potassium Chloride Solution, USP, 10% in Unit Dose. The product is supplied to the market in a 50 count case of 30mL unit dose cups.

14 Dec 2015

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Validus Pharmaceuticals LLC, together with Wood Creek Capital Management, LLC ("Wood Creek"), announced today the acquisition of the U.S. rights to several well-known product lines from Sanofi US: Anzemet (dolasetron mesylate) Injection and Tablets, Claforan (cefotaxime) Injection/IM/IV, Demerol (meperidine hydrochloride) Tablets, Drisdol (ergocalciferol) Capsules and Oral Solution, Hiprex (methenamine hippurate) Tablets, Lasix (furosemide) Tablets, Norpramin (desipramine hydrochloride) Tablets and Trental (pentoxifylline) Tablets.

14 Dec 2015

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease.

14 Dec 2015

CTI BioPharma earns $10 million milestone payment from Teva for TRISENOX (arsenic trioxide)

CTI BioPharma Corp. today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX (arsenic trioxide).

14 Dec 2015

Study offers insight into how female Viagra affects the brain

As the drug touted as "the female Viagra" comes to market, researchers at the University of Wisconsin-Madison are learning more about how the drug, called flibanserin, affects the brain.

13 Dec 2015

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

12 Dec 2015

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

11 Dec 2015

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection.

11 Dec 2015

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

Cardiorentis AG, a privately held biopharmaceutical company, today announced that the U.S. Food and Drug Administration has granted Fast Track status to Ularitide, an investigational therapy for the treatment of acute decompensated heart failure (ADHF).

11 Dec 2015

Findings may lead to new treatment strategy for phobia

A new study published in the latest issue of Biological Psychiatry reports the successful and instant reduction of fear in spider-fearful participants following a 2-minute exposure combined with a single dose of a regular pharmacological treatment.

11 Dec 2015

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.

11 Dec 2015

Pharmaceutical News

Shingles vaccine can help protect elderly patients with end-stage renal disease

TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan

Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

SLU researcher discovered world's first dengue vaccine

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Researchers discover first broad spectrum drug that can potently kill aging cells in culture

Flu vaccine strategy needs to be reworked, York U study finds

Global Health Impact Index can measure actual impact of drugs worldwide

VistaPharm announces launch of Potassium Chloride Solution

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

CTI BioPharma earns $10 million milestone payment from Teva for TRISENOX (arsenic trioxide)

Study offers insight into how female Viagra affects the brain

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

Findings may lead to new treatment strategy for phobia

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News